Results of a new study found that an extended-release form of methylphenidate - sold as CONCERTA® (methylphenidate HCl in the OROS® delivery system) may be associated with a lower likelihood of abuse than immediate-release methylphenidate (sold as Ritalin®). The findings were presented today at a meeting of child and adolescent psychiatrists.
The St. Louis Post-Dispatch on Sunday examined the recent increase in the number of agreements in which brand-name pharmaceutical companies pay generic pharmaceutical companies to delay market entry of their products (Feldstein, St. Louis Post-Dispatch, 10/29). The
The Raleigh News & Observer on Wednesday examined how the expected congressional approval in 2007 of a bill that would renew the FDA Prescription Drug User Fee Act has "pharmaceutical and biotech executives worried" over unrelated provisions that Democrats might attach to the legislation.
A West Virginia rule requiring pharmaceutical companies to disclose their advertising and marketing costs in the state is "all but dead" after the Legislative Rule-Making Review Committee on Tuesday did not act on the measure before adjourning for the year, the
The Bush administration on Monday will propose a rule that would reduce reimbursements to pharmacists for prescription drugs for Medicaid beneficiaries, the New York Times reports. The rule, which would implement provisions of the Deficit Reduction Act signed in February by President Bush, would save $8.4 billion over the next five years, including $4.9 billion in federal savings and $3.